Corporate ActionJul 9, 2026, 04:18 PM
Biodexa Pharmaceuticals to Vote on 1-for-10,000 Share Consolidation
AI Summary
Biodexa Pharmaceuticals PLC has distributed a Notice of General Meeting to shareholders, scheduled for July 29, 2026. The meeting will address a proposed share capital reorganisation, including a 1-for-10,000 share consolidation, followed by a subdivision into new ordinary shares and E deferred shares. This reorganisation aims to rationalize the company's exceptionally large number of outstanding ordinary shares. Additionally, shareholders will vote on authorizing directors to allot shares up to £25,000,000 and to disapply pre-emption rights, along with adopting new articles of association.
Key Highlights
- General Meeting scheduled for July 29, 2026, at 11:00 a.m. (London time).
- Shareholders to vote on a 1-for-10,000 share consolidation of existing ordinary shares.
- Consolidated shares will then be subdivided into one new ordinary share and 9,999 E deferred shares.
- Company currently has 452,032,808,922 ordinary shares outstanding.
- Directors to be authorized to allot shares up to an aggregate nominal value of £25,000,000.00.
- Proposal to disapply statutory pre-emption rights for cash allotments.
- New articles of association to be approved and adopted, conditional on share reorganisation.
Price Impact
More from BDRX